OncoTarget™ and OncoTreat™ Test for Cancer Therapy Selection
Immunotherapy and precision oncology have advanced significantly, highlighting the importance of personalized cancer therapeutics. Patient-specific tumor profiling allows for optimal drug selection, including FDA-approved immunotherapies and investigational agents.
The OncoTarget™ test uses whole-transcriptome sequencing of tumor tissue to identify aberrantly expressed proteins that may serve as therapeutic targets. It currently profiles 193 proteins, which are targeted by 94 FDA-approved drugs and an additional 239 investigational agents in phase II or III clinical trials. The panel is continuously updated as new drugs and targets are validated.
The OncoTreat™ test evaluates the coordinated activity of 6,293 master regulator (MR) proteins within the tumor. By integrating MR analysis with drug perturbation studies in MR-matched cell line models, OncoTreat prioritizes agents most likely to reverse oncogenic activity in a patient’s tumor. Together, OncoTarget™ and OncoTreat™ provide a comprehensive, functional strategy to guide drug prioritization and clinical trial enrollment for patients with treatment-refractory or relapsed cancers.
- Supports precision oncology by identifying actionable therapeutic targets
- Guides the selection of FDA-approved drugs or clinical trial enrollment
- Provides therapeutic options for patients who have failed standard treatments
Not applicable
Fresh frozen tissue or formalin-fixed paraffin-embedded (FFPE).
Whole blood or white blood cells containing ≥50% nucleated cells.
Stability
FFPE blocks stable for months to years.
Blood
- Ambient: 3-5 days
- Refrigerated: 7-14days
- PLoS One. 2025 Jun 11;20(6):e0325769. [PMID: 40498747]
- Nat Genet. 2018 Jul;50(7):979-989. [PMID: 29915428]
- Cancer Discov. 2023 Jun 2;13(6):1386-1407. [PMID: 37061969]
- Med. 2023 Jan 13;4(1):15-30.e8. [PMID: 36513065]